COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy

Current Topics in Medicinal Chemistry

Volumn 7, Issue 3, 2007, Pages 283-296

  Goossens, Laurence ^a   Pommery, Nicole ^a   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Cancer; Cyclooxygenases; Dual inhibitors; Lipoxygenases

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE INHIBITOR; AROMATASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DARBUFELONE; FLUFENAMIC ACID; GEMCITABINE; IBUPROFEN; INDOMETACIN; ISOENZYME; LIPOXYGENASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; POLYUNSATURATED FATTY ACID; ROFECOXIB; S 2474; TEBUFELONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZILEUTON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FATTY ACID METABOLISM; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RISK REDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; HUMANS; LIPOXYGENASE INHIBITORS; NEOPLASMS;

EID: 33847658738     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941369     Document Type: Review

References (175)

1. Shin, Y.K.; Park, J.S.; Kim, H.S.; Jun, H.J.; Kim, G.E.; Suh, C.O.; Yun, Y.S.; Pyo, H. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res. 2005, 65, 9501-9509.
2. Liao, Z.; Komaki, R.; Milas, L.; Yuan, C.; Kies, M.; Chang, J.Y.; Jeter, M.; Guerrero, T.; Blumenschien, G.; Smith, C.M.; Fossella, F.; Brown, B.; Cox, J.D. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 3342-3348.
3. Gore, E. Celecoxib and radiation therapy in non-small-cell lung cancer. Oncology 2005, 18, 10-14.
4. Olsen, S.R. Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. Biomed. Pharmacother. 2005, 59, S306-S310.
5. Govindan, R.; McLeod, H.; Mantravadi, P.; Fineberg, N.; Helft, P.; Kesler, K.; Hamna, N.; Stoner, C.; Ansari, R.; Fox, E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology 2004, 18, 18-21.
6. Pan, C.X; Loehrer, P.; Seitz, D.; Helt P.; Juliar, B.; Ansari, R.; Pletcher, W.; Vinson, J.; Chang, L.; Sweeney, C. A phase II trial of irinitecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology 2005, 69, 63-70.
7. Milella, M.; Gelibter, A.; Di Cosimo, S.; Bria, E.; Ruggeri, E.M.; Carlini, P.; Malaguti, P.; Pellicciotta, M.; Terzoli, E.; Cognetti, F. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101, 133-138.
8. Bundred, N.J.; Barnes, N.L. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br. J. Cancer 2005, 93, S10-S15.
9. Kashfi, K.; Ryann, Y.; Qiao, L.L.; Williams, J.L.; Chen, J.; del Soldato, P.; Traganos, F.; Rigas, B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 2002, 303, 1273-1282.
10. Williams, J.L.; Nath, N.; Chen, J.; Hundley, T.R.; Gao, J.; Kopelovich, L.; Kashfi, K.; Rigas, B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 2003, 63, 7613-7618.
11. Yeh, R.K.; Chen, J.; Williams, J.L.; Baluch, M.; Hundley, T.R.; Rosenbaum, R.E.; Kalala, S.; Traganos, F.; Benardini, F.; del Soldato, P.; Kashfi, K.; Rigas, B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. Pharmacol. 2004, 67, 2197-2205.
12. Huguenin, S.; Fleury-Feith, J.; Kheuang, L.; Jaurand, M.C.; Bolla, M.; Riffaud, J.P.; Chopin, D.K.; Vacherot F. Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 2004, 61, 132-141.
13. Smith, W.L.; Garavito, R.M.; DeWitt, D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996, 271, 33157-33160.
14. Dannenberg, A.J.; Subbaramaiah, K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003, 4, 431-436.
15. Chadrasekkharan, N.V.; Dai, H.; Roos, K.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs cloning, structure and expression. Proc. Natl. Acad. Sci. USA 2002, 99, 13926-13931.
16. Dempke, W.; Rie, C.; Grothey, A.J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 2001, 127, 411-417.
17. Hussain, T.; Gupta, S.; Mukhtar, H.; Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003, 191, 125-135.
18. Chun, K.S.; Surb, Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 2004, 68, 1089-1100.
19. Sheng, H.; Shao, J.; DuBois, R.N. K-ras-mediated increase in cyclooxygenase-2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 2001, 61, 2670-2675.
20. Araki, Y.; Okamura, S.; Hussain, S.P.; Nagashima, M.; He, P.; Shiseki, M.; Miura, K.; Harris, C.C. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 2003, 63, 728-734.
21. Hwang, D.; Jang, B.C.; Yu, G.; Boudreau, M. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide. Biochem. Pharmacol. 1997, 54, 87-96.
22. Mestre, J.R.; Mackrell, P.J.; Rivadeneira, D.E.; Stapleton, P.P.; Tanabe, T.; Daly, J.M. Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells. J. Biol. Chem. 2001, 279, 3977-3982.
23. Gorgoni, B.; Caivano, M.; Arizmendi, C.; Poli, V. The transcription factor C/EBPb is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts. J. Biol. Chem. 2001, 276, 40769-40777.
24. Subbaramaiah, K.; Altorki, N.; Chung, W.J.; Mestre, J.R.; Sampat, A.; Dannenberg, A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 1999, 274, 10911-10915.
25. Subbaramaiah, K.; Lin, D.T.; Hart; J.C.; Dannenberg, A.J. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J. Biol. Chem. 2001, 276, 12440-12448.
26. Rigas, B.; Goldman, I.S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122, 518-523.
27. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 1994, 107, 1183-1188.
28. Panel, V.; Boelle, P.Y.; Ayala-sanmartin, J.; Jouniaux, A.M.; Hamelin, R.; Masliah, J.; Trugnan, G.; Flejou, J.F.; Wendum, D. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett. 2006, ahead of print.
29. Castellone, M.D.; Teramoto, H.; William, B.O.; Druey, K.M.; Gutkind, J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310, 1504-1510.
30. Buchanan, F.G.; DuBois, R.N. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006, 9, 6-8.
31. Dial, E.J.; Doyen J.R.; Lichtenberger, L.M. Phosphaditylcholine associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro. Cancer Chemother. Pharmacol. 2006, 57, 295-300.
32. Yang, W. L.; Roland, I.H.; Godwin A.K.; Xu, X.X. Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. Oncogene 2005, 24, 7991-8002.
33. Sakamoto, A.; Yokoyama, Y.; Umemoto, M.; Futagami, M.; Sakamoto, T.; Bing, X.; Mizunuma, H. Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumors. Br. J. Cancer 2004, 91, 633-638.
34. Fujimoto, J.; Toyoki, H.; Sakaguchi H.; Jahan, I.; Alam, S.M.; Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol. Rep. 2006, 15, 21-25.
35. Garcea, G.; Dennison; A.R.; Steward, W.P.; Berry, D.P. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005, 5, 514-529.
36. Ding, X.Z.; Tong, W.G.; Adrian, T.E. Blockade of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic cancer cells. Anticancer Res. 2000, 20, 2625-2631.
37. Kong, G.; Kim, E.K.; Kim, W.S.; Lee, K.T.; Lee Y.W.; Lee, J.K.; Paik, S.W.; Rhee, J.C. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J. Gastroenterol Hepatol. 2002, 17, 914-921.
38. 2 is generated by specific COX-2 activity and increases VEGF production in COX-2 expressing human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2003, 306, 887-897.
39. Chu, J.; Lloyd, F.L.; Trifan O.C.; Knapp B.; Rizzo, M.T. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth of pancreatic cancer. Mol. Cancer Ther. 2003, 2, 1-7.
40. Eibl, G.; Takata, Y.; Boros, L.G.; Liu, J.; Okada, Y.; Reber, H.A.; Hines, O.J. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res. 2005, 65, 982-990.
41. Ferrari, V.; Valcamonico, F.; Amoroso, V.; Simoncini, E.; Vassali, L.; Marpicati, P.; Rangoni, G.; Grisanti, S.; Tiberio, G.A.; Nodari, F.; Strina, C.; Marini, G. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother. Pharmacol. 2006, 57, 185-190.
42. Basu, G.D.; Pathangey, L.B.; Tinder, T.L.; Gendler S.J.; Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7, 422-435.
43. Subbaramaiah, K.; Norton, L.; Gerald, W.; Dannenberg, A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J. Biol. Chem. 2002, 277, 18649-18657.
44. Sivula, A.; Talvensaari-Mattila, A.; Lundin, J.; Joensuu, H.; Haglund, C., Ristimaki, A.; Turpeenniemi-Hujanen, T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res. Treat. 2005, 89, 215-220.
45. Chow, L.W.; Loo, W.T.; Toi, M. Current directions for COX-2 inhibition in breast cancer. Biomed. Pharmacother. 2005, 59, S281-284.
46. Wang, W.; Bergh, A.; Damber, J.E. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin. Cancer Res. 2005, 11, 3250-3256.
47. Gupta, S.; Srivastava, M.; Ahmad, N.; Bostwick, D.G.; Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000 42, 73-78.
48. Kirschenbaum, A.; Liu, X.H.; Yao, S.; Levine, A. The role of cyclooxygenase-2 in prostate cancer. Urology 2000, 58, 127-131.
49. Sabichi, A.L.; Subbarayan, V.; Llansa, N.; Lippman, S.M.; Menter, D.G. Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1704-1709.
50. Dandekar, D.S.; Lopez, M.; Carey, R.I.; Lokeshwar, B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 2005, 115, 484-492.
51. Méric, J.B.; Rottey, S.; Olaussen, K.; Soria, J.C.; Khayat D.; Rixe, O.; Spano, J.P. Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. 2006, in press.
52. Gasparini, G.; Longo, R.; Sarmiento, R.; Morabito, A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003, 4, 605-615.
53. Zha, S.; Yegnasubramanian, V.; Nelson, W.G.; Isaacs, W.B.; De Matzo, A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004, 215, 1-20.
54. Kashfi, K.; Rigas, B. Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol. 2005, 70, 969-986.
55. Sun, Y.; Tang, X.M.; Half, E.; Kuo, M.T.; Sinicrope, F.A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002, 62, 6323-6328.
56. Hwang, D. H.; Fung, V.; Dannenberg, A.J. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 2002, 4, 91-97.
57. Zhang, X.; Morham, S.G.; Langenbach, R.; Young D.A. Malignant transformation of antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 1999, 190, 451-460.
58. Dannenberg, A.J.; Lippman, S.M.; Mann, J.R.; Subbaramatiah, K.; DuBois, R. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. 2005, 23, 254-266.
59. Li, G.; Yang, T.; Yan, J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem. Biophys. Res. Commun. 2002, 299, 886-890.
60. Kinugasa, Y.; Hatori, M.; Ito, H.; Kurihara, Y.; Ito, D.; Nagumo, M. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin. Exp. Metastasis 2004, 21, 737-745.
61. Ishizaki, T.; Katsumata, K.; Tsuchida, A.; Wada, T.; Mori, Y.; Hisada, M.; Kawakita, H.; Aoki, T. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int. J. Mol. Med. 2006, 17, 357-362.
62. Prescott, S.M. Is cyclooxygenase-2 the alpha and the omega in cancer? J. Clin. Invest. 2000, 105, 1511-1512.
63. Leahy, K.M.; Ornberg, R.L.; Wang, Y.; Zweifel, B.S.; Koki, A.T.; Masferrer, J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002, 62, 625-631.
64. Pathak, S.K.; Sharma, R.A.; Steward, W.P.; Mellon, J.K.; Griffiths, T.R.L.; Gescher, A.J. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur. J. Cancer 2005, 41, 61-70.
65. Arico, S.; Pattingre, S.; Bauvy, C; Gane, P.; Barbat, P.; Codogno, P.; Ogier-Denis, E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in human colon cancer HT-29 cell line. J. Biol. Chem. 2002, 277, 27613-27621.
66. Takahashi, Y.; Kawahara, F.; Noguchi, M.; Miwa, K.; Sato, H.; Seiki, M.; Inoue, H.; Tanabe, T.; Yoshimoto, T. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 1999, 460, 145-148.
67. Callejas, N.A.; Casado, M.; Diaz-Guerra, M.J.; Bosca, L.; Martin-Sanz, P. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinases-2 and -9 in fetal rats hepatocytes. Hepatology 2001, 33, 860-867.
68. Gately, S.; Li, W.W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 2004, 31, 2-11.
69. Wu, G.; Luo, J.; Rana, J.S.; Laham, R.; Sellke, S.W.; Li, J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc. Res. 2006, 69, 512-519.
70. Jones, M.K.; Wang, H.; Peskar, B.M.; Levin, E.; Itani, R.M.; Sarfeh, I.J.; Tamawski, A.M. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight intro mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 1999, 5, 1418-1423.
71. Shiff, S.J.; Rigas, B. Aspirin for cancer. Nat. Med. 1999, 5, 1348-1349.
72. Dogné, J.M.; Supuran, C.T; Pratico, D. Adverse cardiovascular effects of the Coxibs. J. Med. Chem. 2005, 48, 1-7.
73. Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286, 954-959.
74. FitzGerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351, 1709-1711.
75. Pereg, D.; Lishner, M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J. Int. Med. 2005, 258, 115-123.
76. White, W.B.; Faich, G.; Whelton, A.; Maurath, C.; Ridge, N.J.; Verbug, K.M.; Geis, G.S.; Lefkowith, J.B. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenao. Am. J. Cardiol. 2002, 89, 425-430.
77. Steele, V.E.; Holmes, C.A.; Hawk, E.T.; Kopelovich, L.; Lubet, R.A.; Crowell, J.A.; Sigman, C.C.; Kelloff, G.J. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 467-483.
78. Shureiqi, I.; Lippman, S.M. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001, 61, 6307-6312.
79. Kennedy, T.J.; Chan, C-Y.; Ding, X-Z.; Adrian, T.E. Lipoxygenase inhibitors for the treatment of pancreatic cancer. Expert Rev. Anticancer Ther. 2003, 3, 525-536.
80. Nie, D.; Honn, K.V. Eicosanoid regulation of angiogenesis in tumors. Semin. Thromb. Hemost. 2004, 30, 119-125.
81. Catalano, A.; Procopio, A. New aspects on the role of lipoxygenases in cancer progression. Histol. Histopathol. 2005, 20, 969-975.
82. Pommery, N.; Massingham, R.; Hénichart, J-P. 5-lipoxygenase inhibitors - patent and literature activity during 2001-2004. Expert Opin. Ther. Patents 2006, 16, 13-26.
83. Matsuyama, M.; Yoshimura, R.; Mitsuhashi, M.; Tsuchida, K.; Takemoto, Y.; Kawahito, Y.; Sano, H.; Nakatani, T. 5-lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol. Rep. 2005, 14, 73-79.
84. Chen, X.; Wang, S.; Wu, N.; Sood, S.; Wang, P.; Jin, Z.; Beer, D.G.; Giordano, T.J.; Lin, Y.; Shih, W.C.; Lubet, R.A.; Yang, C.S. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res. 2004, 10, 6703-6709.
85. Hoque, A.; Lippman, S.M.; Wu, T.T.; Xu, Y.; Liang, Z.D.; Swisher, S.; Zhang, H.; Cao, L.; Ajani, J.A.; Xu, X.C. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005, 26, 785-791.
86. Avis, I.; Hong, S.H.; Martinez, A.; Moody, T.; Choi, Y.H.; Trepel, J.; Das, R.; Jett, M.; Mulshine, J.L. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 2001, 15, 2007-2009.
87. Tong, W.G.; Ding, X.Z.; Adrian, T.E. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem. Biophys. Res. Commun. 2002, 296, 942-948.
88. Kim, J.H.; Hubbard, N.E.; Ziboh, V.; Erickson, K.L. Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein. Biochim. Biophys. Acta 2005, 1736, 244-250.
89. Jiang, W.G.; Douglas-Jones, A.; Mansel, R.E. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69, 275-281.
90. Wang, Y.; Zhou, B.; Li, J.; Cao, Y.B.; Chen, X.S.; Cheng, M.H.; Yin, M. Inhibitors of 5-lipoxygenase inhibit expression of intercellular adhesion molecule-1 in human melanoma cells. Acta Pharmacol. Sin. 2004, 25, 672-677.
91. Nielsen, C.K.; Ohd, J.F.; Wikstrom, K.; Massoumi, R.; Paruchuri, S.; Juhas, M.; Sjolander, A. The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. Adv. Exp. Med. Biol. 2003, 525, 201-204.
92. Paruchuri, S.; Broom, O.; Dib, K.; Sjolander, A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol. Chem. 2005, 280, 13538-13544.
93. Ye, Y.N.; Wu, W.K.; Shin, V.Y.; Cho, C.H. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur. J. Pharmacol. 2005, 519, 52-57.
94. Hennig, R.; Grippo, P.; Ding, X.Z.; Rao, S.M.; Buchler, M.W.; Friess, H.; Talamonti, M.S.; Bell, R.H.; Adrian, T.E. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005, 65, 6011-6016.
95. Ding, X.Z.; Talamonti, M.S.; Bell, R.H. Jr; Adrian, T.E. A novel anti-pancreatic cancer agent, LY-293111. Anticancer Drugs 2005, 16, 467-473.
96. Edderkaoui, M.; Hong, P.; Vaquero, E.C.; Lee, J.K.; Fischer, L.; Friess, H.; Buchler, M.W.; Lerch, M.M.; Pandol, S.J.; Gukovskaya, A.S. Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289, G1137-G1147.
97. Nie, D.; Che, M.; Grignon, D.; Tang, K.; Honn, K.V. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 2001, 20, 195-206.
98. Matsuyama, M.; Yoshimura, R.; Mitsuhashi, M.; Hase, T.; Tsuchida, K.; Takemoto, Y.; Kawahito, Y.; Sano, H.; Nakatani, T. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int. J. Oncol. 2004, 24, 821-827.
99. Moretti, R.M.; Montagnani Marelli, M.; Sala, A.; Motta, M.; Limonta, P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer 2004, 112, 87-93.
100. Powell, W.S.; Rokach, J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog. Lipid Res. 2005, 44, 154-183.
101. Sundaram, S.; Ghosh, J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem. Biophys. Res. Commun. 2006, 339, 93-98.
102. Timar, J.; Raso, E.; Dome, B.; Li, L.; Grignon, D.; Nie, D.; Honn, K.V.; Hagmann, W. Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int. J. Cancer 2000, 87, 37-43.
103. Lovat, P.E.; Corazzari, M.; Goranov, B.; Piacentini, M.; Redfern, C.P. Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Ann. NY Acad. Sci. 2004, 1028, 81-89.
104. Raso, E.; Dome, B.; Somlai, B.; Zacharek, A.; Hagmann, W.; Honn, K.V.; Timar, J. Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. Melanoma Res. 2004, 14, 245-250.
105. Yoshimura, R.; Matsuyama, M.; Mitsuhashi, M.; Takemoto, Y.; Tsuchida, K.; Kawahito, Y.; Sano, H.; Nakatani, T. Relationship between lipoxygenase and human testicular cancer. Int. J. Mol. Med. 2004, 13, 389-393.
106. Ikemoto, S.; Sugimura, K.; Kuratukuri, K.; Nakatani, T. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2). Anticancer Res. 2004, 24, 733-736.
107. Yoshimura, R.; Inoue, K.; Kawahito, Y.; Mitsuhashi, M.; Tsuchida, K.; Matsuyama, M.; Sano, H.; Nakatani, T. Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. Int. J. Mol. Med. 2004, 13, 41-46.
108. Shureiqi, I.; Wu, Y.; Chen, D.; Yang, X.L.; Guan, B.; Morris, J.S.; Yang, P.; Newman, R.A.; Broaddus, R.; Hamilton, S.R.; Lynch, P.; Levin, B.; Fischer, S.M.; Lippman, S.M. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005, 65, 11486-11492.
109. Shureiqi, I.; Chen, D.; Lotan, R.; Yang, P.; Newman, R.A.; Fischer, S.M.; Lippman, S.M. 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000, 60, 6846-6850.
110. Heslin, M.J.; Hawkins, A.; Boedefeld, W.; Arnoletti, J.P.; Frolov, A.; Soong, R.; Urist, M.M.; Bland, K.I. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann. Surg. 2005, 241, 941-946.
111. Hsi, L.C.; Xi, X.; Wu, Y.; Lippman, S.M. The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Mol. Cancer Ther. 2005, 4, 1740-1746.
112. Hsi, L.C.; Xi, X.; Lotan, R.; Shureiqi, I., Lippman, S.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004, 64, 8778-8781.
113. Zuo, X.; Wu, Y.; Morris, J.S.; Stimmel, J.B.; Leesnitzer, L.M.; Fischer, S.M.; Lippman, S.M.; Shureiqi, I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 2005, 25, 1225-1241.
114. Kim, J.S.; Baek, S.J.; Bottone, F.G. Jr; Sali, T.; Eling, T.E. Overexpression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol. Cancer Res. 2005, 3, 511-517.
115. Kelavkar, U.P.; Nixon, J.B.; Cohen, C.; Dillehay, D.; Eling, T.E.; Badr K.F. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001, 22, 1765-1773.
116. Kelavkar, U.P.; Cohen, C. 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 2004, 6, 41-52.
117. Kelavkar, U.P.; Glasgow, W.; Olson, S.J.; Foster, B.A.; Shappell, S.B. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 2004, 6, 821-830.
118. Shappell, S.B.; Gupta, R.A.; Manning, S.; Whitehead, R., Boeglin, W.E.; Schneider, C.; Case, T.; Price, J.; Jack, G.S.; Wheeler, T.M.; Matusik, R.J.; Brash, A.R.; DuBois, R.N. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor g and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001, 61, 497-503.
119. Hsi, L.C.; Wilson, L.C.; Eling, T.E. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. J. Biol. Chem. 2002, 277, 40549-40556.
120. Pham, H.; Banerjee, T.; Nalbandian, G.M.; Ziboh, V.A. Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett. 2003, 189, 17-25.
121. Gonzalez, A.L.; Roberts, R.L.; Massion, P.P.; Olson, S.J.; Shyr, Y.; Shappell, S.B. 15-lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. Hum. Pathol. 2004, 35, 840-849.
122. Nony, P.A.; Kennett, S.B.; Glasgow, W.C.; Olden, K.; Roberts, J.D. 15S-lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6 and p38 MAPK. J. Biol. Chem. 2005, 280, 31413-31419.
123. Yu, K.: Bayona, W.; Kallen, C.B.; Harding, H.P.; Ravera, C.P.; McMahon, G.; Brown, M.; Lazar, M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 1995, 270, 23975-23983.
124. Li, N.; Sood, S.; Wang, S.; Fang, M.; Wang, P.; Sim, Z.; Yang, C.S.; Chen, X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin. Cancer Res. 2005, 11, 2089-2096.
125. Romano, M.; Claria, J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003, 17, 1986-1995.
126. Tsujii, M., Kawano, S.; Tsuji, S.; Sawaoka, M.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-716.
127. Bunn, P.A.; Keith, R.L. The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer. Clin. Lung Cancer 2002, 3, 271-277.
128. Fujita, H.; Koshida, K.; Keller, E.T.; Takahashi, Y.; Yoshimito, T.; Namiki, M.; Mizokami, A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002, 53, 232-240.
129. Schroeder, C.P.; Yang, P.; Newman, R.A.; Lotan, R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol. Ther. 2004, 3, 847-852.
130. Ye, Y.N.; Wu, W.K.; Shin, V.Y.; Bruce, I.C.; Wong, B.C.; Cho, C.H. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005, 26, 827-834.
131. Nielsen, C.K.; Campbell, J.I.; Ohd, J.F.; Morgelin, M.; Riesbeck, K.; Landberg, G.; Sjolander, A. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res. 2005, 65, 732-742.
132. Ye, Y.N.; Liu, E.S.L.; Shin, V.Y.; Wu, W.K.K.; Cho, C.H. The modulating role of nuclear factor-kB in the action of a7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 2004, 311, 123-130.
133. Rioux, N.; Castonguay, A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998, 19, 1393-1400.
134. Johnsen, J.I.; Lindskog, M.; Ponthan, F.; Pettersen, I.; Elfman, L.; Orrego, A.; Sveinbjornsson, B.; Kogner, P. NSAIDs in neuroblastoma therapy. Cancer Lett. 2005, 228, 195-201.
135. Gugliucci, A.; Ranzato, L.; Scorrano, L.; Colonna, R.; Petronilli, V.; Cusan, C.; Prato, M.; Mancini, M.; Pagano, F.; Bernardi, P. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J. Biol. Chem. 2002, 277, 31789-31795.
136. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
137. Buijsman, R.C.; Basten, J.E.; van Dinther, T.G.; van de Marel, G.A.; van Boeckel, C.A.; van Boom, J.H. Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action. Bioorg. Med. Chem. Lett. 1999, 9, 2013-2018.
138. Jacobson, K.A.; Xie, R.; Young, L.; Chang, L.; Liang, B.T. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. J. Biol. Chem. 2000, 275, 30272-30279.
139. Gardiner, S.M.; March, J.E.; Kemp, P.A.; Mullins, J.J.; Bennett, T. Hemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol. 1995, 116, 2237-2244.
140. Walsh, T.; Fitch, K.; Williams, D.; Murphy, K.; Nolan, N.; Pettibone, D.; Chang, R.; O'Malley, S.; Clineschmidt, B.; Veber, D.; Greenlee, W. Potent dual antagonists of endothelin and angiotensin II receptors derived from a-phenoxyphenylacetic acids (Part III). Bioorg. Med. Chem. Lett. 1995, 5, 1155-1158.
141. Murugesan, N.; Tellew, J.; Gu, Z.; Kunst, B.; Fadnis, L.; Cornelius, L.; Baska, R.; Yang, Y.; Beyer, S.; Monshizadegan, H.; Dickinson, K.; Panchal, B.; Valentine, M.; Chong, S.; Morrison, R.; Carlson, K.; Powell, J.; Moreland, S.; Barrish, J.; Kowala, M.; Macor, J. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J. Med. Chem. 2002, 45, 3829-3835.
142. Portoghese, P.S. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 2001, 44, 2259-2269.
143. Di Napoli, M.; Papa, F. NCX-4016 NicOX. Curr. Opin. Invest. Drugs 2003, 4, 1126-1139.
144. Lolli, M.L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Coruzzi, G.; Manarini, S.; Fruttero, R.; Gasco, A. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem. 2001, 44, 3463-3468.
145. 2 receptors. Bioorg. Med. Chem. Lett. 1996, 6, 951-956.
146. 1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg. Med. Chem. Lett. 2002, 12, 261-264.
147. Lewis, T.; Bayless, L.; Eckman, J.; Ellis, J.; Grewal, G.; Libertine, L.; Nicolas, J.; Scannell, R.; Wels, B.; Wenberg, K.; Wypij, D. 5-Lipoxygenase inhibitors with histamine H1 receptor antagonist activity. Bioorg. Med. Chem. Lett. 2004, 14, 2265-2268.
148. 1 dual antagonizing activity. 1. J. Med. Chem. 1993, 36, 417-420.
149. 2 ligands. Pharm. Pharmacol. Commun. 1999, 5, 169-171.
150. Millet, R.; Goossens, J-F.; Bertrand-Caumont, K.; Houssin, R.; Hénichart, J-P. Synthesis and biological evaluation of tripeptides
151. Millet, R.; Domarkas, J.; Rigo, B.; Goossens, L.; Goossens, J-F.; Houssin, R.; Hénichart, J-P. Novel potent Substance P and Neurokinin A receptor antagonists. Conception, synthesis and biological evaluation of indolizine derivatives. Bioorg. Med. Chem., 2002, 10, 2905-2912.
152. Bailly, C.; Pommery, N.; Hénichart, J.P. DNA-synthesis and tumor growth inhibitions of AGGA, a bleomycin-amsacrine hybrid derivative. Cancer Lett., 1988, 38, 321-328.
153. Bailly, C.; Leclere V.; Pommery, N.; Colson, P.; Houssier, C.; Rivalle, C.; Bisagni, E.; Hénichart, J.P. Binding to DNA, cellular uptake and biological activity of a distamycin-ellipticine hybrid molecule. Anti-CancerDrug Design, 1993, 8, 145-164.
154. Hénichart, J.P.; Waring, M.J.; Riou, J.F.; Denny, W.A.; Bailly, C. Copper-dependent oxidative and topoisomerase II- mediated DNA cleavage by a netropsin-acridin combilexin. Mol. Pharmacol., 1997, 51, 448-461.
155. Boitte, N.; Pommery, N.; Colson, P.; Houssier, C.; Waring, M.J.; Hénichart, J.P.; Bailly, C.; Synthesis, DNA-binding, and cytotoxic properties of a bis (netropsin) - anthracenedione conjugate. Anti-CancerDrug Design, 1997, 12, 481-501.
156. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38, 645-659.
157. Unangst, P.C.; Connor, D.T.; Cetenko, W.A.; Sorenson, R.J.; Kostlan, C.R.; Sircar, J.C.; Wright, C.D.; Schrier, D.J.; Dyer, R.D. Synthesis and biological evaluation of 5- 3,5-bis(1,1-dimethylethyl) -4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J. Med. Chem. 1994, 37, 322-328.
158. Kulkarni, S.; Das, S.; Funk, C.D.; Murray, D.; Cho, W. Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J. Biol. Chem. 2002, 277, 13167-13174.
159. Inagaki, M.; Tsuri, T.; Jyoyama, H.; Ono, T.; Yamada, K.; Kobayashi, M.; Hori, Y.; Arimura, A.; Yasui, K.; Ohno, K.; Kakudo, S.; Koizumi, K.; Suzuki, R.; Kawai, S.; Kato, M.; Matsumoto, S. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. J. Med. Chem. 2000, 43, 2040-2048.
160. Janusz, J.M.; Young, P.A.; Ridgeway, J.M.; Scherz, M.W.; Enzweiler, K.; Wu, L.I.; Gan, L.; Chen, J.; Kellstein, D.E.; Green, S.A.; Tulich, J.L.; Rosario-Jansen, T.; Magrisso, I.J.; Wehmeyer, K.R.; Kuhlenbeck, D.L.; Eichhold, T.H.; Dobson, R.L. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position. J. Med. Chem. 1998, 41, 3515-3529.
161. Kirchner, T.; Argentieri, D.C.; Barbone, A.G.; Singer, M.; Steber, M.; Ansell, J.; Beers, S.A.; Wachter, M.P.; Wu, W.; Malloy, E.; Stewart, A.; Ritchie, D.M. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J. Pharmacol. Exp. Ther. 1997, 282, 1094-1101.
162. Kolasa, T.; Brooks, C.D.; Rodriques, K.E.; Summers, J.B.; Dellaria, J.F.; Hulkower, K.I.; Bouska, J.; Bell, R.L.; Carter, G.W. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J. Med. Chem. 1997, 40, 819-824.
163. Boschelli, D.H.; Connor, D.T.; Hoefle, M.; Bornemeier, D.A.; Dyer, R.D. Conversion of NSAIDS into balanced dual inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg. Med. Chem. Lett. 1992, 2, 69-72.
164. Jahng, Y.; Zhao, L.X.; Moon, Y.S.; Basnet, A.; Kim, E.K.; Chang, H.W.; JU, H.K.; Jeong, T.C.; Lee, E.S. Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory acticities. Bioorg. Med. Chem. Lett. 2004, 14, 2559-2562.
165. Rao, P.N.P.; Chen, Q.H.; Knaus, E.E. Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenase. Bioorg. Med. Chem. Lett. 2005, 15, 4842-4845.
166. Rao, P.N.P.; Chen, Q.H.; Knaus, E.E. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. J. Med. Chem. 2006, 49, 1668-1683.
167. Connolly, P.J.; Wetter, S.K.; Beers, K.N.; Hamel, S.C.; Chen, R.H.; Wachter, M.P.; Ansell, J.; Singer, M.M.; Steber, M.; Ritchie, D.M.; Argentieri, D.C. N-Hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg. Med. Chem. Lett. 1999, 9, 979-984.
168. Rotondo, S.; Dell'Elba, G.; Krauze-Brzosko, K.; Manarini, S.; Martelli, N.; Pecce, R.; Evangelista, V.; Cerletti, C. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function. Eur. J. Pharmacol. 2002, 453, 131-139.
169. Fiorucci, S.; Meli, R.; Bucci, M.; Cirino, G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 2001, 62, 1433-1438.
170. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Hénichart, J-P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/ 5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 779-782.
171. Schneider, I.; Bucar, F. Lipoxygenase inhibitors from natural plant sources. Part 1: Medicinal plants with inhibitory activity on arachidonate 5-lipoxygenase and 5-lipoxygenase/cyclooxygenase. Phytother. Res. 2005, 19, 81-102.
172. Claria, J.; Romano, M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr. Pharm. Des. 2005, 11, 3431-3447.
173. Pommery, N.; Taverne, T.; Telliez, A.; Goossens, L.; Charlier, C.; Pommery, J.; Goossens, J-F.; Houssin, R.; Durant, F.; Hénichart, J-P. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J. Med. Chem. 2004, 47, 6195-6206.
174. Charlier, C.; Hénichart, J.P.; Durant, F.; Wouters, J. Structuralinsights into Human 5-Lipoxygenase Inhibition: combined ligand-based and target-based approach. J. Med. Chem. 2006, 49, 186-195.
175. Pommery, N.; Hénichart, J-P. Involvement of PI3K/Akt pathway in prostate cancer - potential strategies for developing targeted therapies. Mini Rev Med Chem. 2005, 5, 1125-1132.